For patients not currently taking naldemedine AND for patients currently taking naldemedine tablets, non-formulary naldemedine (Symproic®) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of opioid induced constipation in an adult with an active opioid prescription

- AND -

- Prescribed by an Oncologist, or a Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program, or after consultation with a Pain Management Specialist

- AND -

- Patient has failed a trial of at least 2 weeks or had an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action^ and route of administration: polyethylene glycol (MiraLAX), lactulose or sorbitol, senna and bisacodyl. These agents should be used in combination regularly to be effective in management of opioid-induced constipation.

^ e.g. osmotic with stimulant (polyethylene glycol and senna and/or bisacodyl suppository)